The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

The United States Food and Drug Administration (FDA) has suspended the licence of one of the two chikungunya vaccines ...

By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

US health authorities have suspended the licence for the Ixchiq vaccine against the chikungunya virus following reports of “serious adverse events”, the drug’s French maker said Monday.

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.

Analysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...